Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus

The PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) enzyme interferes with the metabolism of low-density lipoprotein (LDL) cholesterol. Inhibition of PCSK9 results in lower LDL cholesterol levels, which can be achieved by different molecular pathways. Monoclonal antibodies targeting circulatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakocevic, Jelena, Dobric, Milan, Vucic, Rada, Furtula, Matija, Zaletel, Ivan, Milutinovic, Katarina, Ilijevski, Ana, Borovic, Milica Labudovic, Tomasevic, Miloje, Bajcetic, Milos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056056/
https://www.ncbi.nlm.nih.gov/pubmed/36983086
http://dx.doi.org/10.3390/ijms24066012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056056/
https://www.ncbi.nlm.nih.gov/pubmed/36983086
http://dx.doi.org/10.3390/ijms24066012

Ejemplares similares